Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.37 |
| ▸ | UBE2M | P61081 | 5/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | USP19 | O94966 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426139 | 0.92 | FAAH (0.51) | FAAHCES2RAD52CCR5OPRM1 | |
| SCHEMBL14950179 | 0.89 | FAAH (0.50) | FAAHCES2CCR5UBE2MDCUN1D1 | |
| SCHEMBL425070 | 0.89 | FAAH (0.50) | FAAHCES2OPRM1OPRD1OPRK1 | |
| SCHEMBL14938037 | 0.89 | FAAH (0.49) | FAAHCES2CCR5UBE2MDCUN1D1 | |
| SCHEMBL427918 | 0.88 | FAAH (0.47) | FAAHCES2CCR5OPRM1OPRD1 | |
| SCHEMBL427420 | 0.87 | FAAH (0.48) | FAAHCES2CCR5OPRM1OPRD1 | |
| SCHEMBL425027 | 0.87 | DRD2 (0.49) | FAAHCES2OPRM1OPRD1OPRK1 | |
| SCHEMBL426174 | 0.86 | FAAH (0.47) | FAAHCES2CCR5UBE2MDCUN1D1 | |
| SCHEMBL14937934 | 0.86 | FAAH (0.47) | FAAHCES2CCR5DCUN1D1 | |
| SCHEMBL15554007 | 0.86 | FAAH (0.64) | FAAHCES2AOC3USP19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885RAD52 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.